Trexquant Investment Lp buys $4.2 Million stake in Hologic (HOLX)

Hologic (HOLX) : Trexquant Investment Lp scooped up 42,100 additional shares in Hologic during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 11, 2016. The investment management firm now holds a total of 125,900 shares of Hologic which is valued at $4.2 Million.Hologic makes up approximately 0.51% of Trexquant Investment Lp’s portfolio.

Other Hedge Funds, Including , Pax World Management reduced its stake in HOLX by selling 80,558 shares or 38.72% in the most recent quarter. The Hedge Fund company now holds 127,500 shares of HOLX which is valued at $4.3 Million. Hologic makes up approx 0.23% of Pax World Management’s portfolio.State Treasurer State Of Michigan reduced its stake in HOLX by selling 12,380 shares or 12.73% in the most recent quarter. The Hedge Fund company now holds 84,900 shares of HOLX which is valued at $2.9 Million. Hologic makes up approx 0.02% of State Treasurer State Of Michigan’s portfolio.Public Employees Retirement Association Of Colorado reduced its stake in HOLX by selling 3,866 shares or 0.85% in the most recent quarter. The Hedge Fund company now holds 450,900 shares of HOLX which is valued at $15.1 Million. Hologic makes up approx 0.12% of Public Employees Retirement Association Of Colorado’s portfolio.Dupont Capital Management Corp boosted its stake in HOLX in the latest quarter, The investment management firm added 80,400 additional shares and now holds a total of 202,900 shares of Hologic which is valued at $6.8 Million. Hologic makes up approx 0.16% of Dupont Capital Management Corp’s portfolio.

Hologic opened for trading at $33.8 and hit $34.29 on the upside on Monday, eventually ending the session at $34.11, with a gain of 1.07% or 0.36 points. The heightened volatility saw the trading volume jump to 21,60,087 shares. Company has a market cap of $9,511 M.

On the company’s financial health, Hologic reported $0.47 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $0.46. The company had revenue of $693.30 million for the quarter, compared to analysts expectations of $687.43 million. The company’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.41 EPS.

Many Wall Street Analysts have commented on Hologic. Hologic was Downgraded by Needham to ” Hold” on Apr 28, 2016.

Hologic Inc. is a developer manufacturer and supplier of diagnostics products medical imaging systems and surgical products. The Company’s business units are focused on diagnostics breast health GYN surgical and skeletal health. The Company’s diagnostics products include Aptima family of assays its ThinPrep system the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases chlamydia and gonorrhea certain high-risk strains of human papillomavirus (HPV) and Trichomonas vaginalis the parasite that causes trichomoniasis. The Company’s GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems an ultrasound-based osteoporosis assessment product and its Fluoroscan mini C-arm imaging products.

Leave a Reply

Hologic - Is it time to Sell?

Top Brokerage Firms are advising their investors on Hologic. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.